The production facility is located within the Technopolis Moscow ASEZ. The construction of the new production facility was successfully completed at the end of last year, and it is currently operating at full capacity.
“The plant has the capacity to produce about 5.5 million vials of live vaccines, 10 million vials of liquid immunobiologicals, and over 5.1 million vials of chemopharmaceuticals annually. All these products are actively utilized to replace imported alternatives,” Vladimir Efimov, Deputy Mayor of Moscow for Economic Policy and Property Relations in Land, said in a statement.
After the facility’s launch, the production of immunobiologicals for small pets in the Technopolis Moscow ASEZ increased by 30% in the first half of 2023. And sales of certain drugs in this segment increased by 5-6 times in 2023.
The project received 2 billion rubles in investments. The facility was designed in compliance with international standards for pharmaceutical production, and in 2023, it obtained the Turkish GMP certificate, enabling the company to supply its products to this market. “The company plans to export up to 10 million doses of vaccines annually,” Gennady Degtev, Director General for the Technopolis Moscow ASEZ, said in a comment.
